Skip to main content
padlock icon - secure page this page is secure

Open Access lncRNA NORAD Contributes to Colorectal Cancer Progression by Inhibition of miR-202-5p

Download Article:
 Download
(HTML 46.5 kb)
 
or
 Download
(PDF 633.2 kb)
 
Previous study indicates that long noncoding RNA NORAD could serve as a competing endogenous RNA to pancreatic cancer metastasis. However, its role in colorectal cancer (CRC) needs to be investigated. In the present study, we found that the expression of NORAD was significantly upregulated in CRC tissues. Furthermore, the expression of NORAD was positively related with CRC metastasis and patients’ poor prognosis. Knockdown of NORAD markedly inhibited CRC cell proliferation, migration, and invasion but induced cell apoptosis in vitro. In vivo experiments also indicated an inhibitory effect of NORAD on tumor growth. Mechanistically, we found that NORAD served as a competing endogenous RNA for miR-202-5p. We found that there was an inverse relationship between the expression of NORAD and miR-202-5p in CRC tissues. Moreover, overexpression of miR-202-5p in SW480 and HCT116 cells significantly inhibited cellular proliferation, migration, and invasion. Taken together, our study demonstrated that the NORAD/miR-202-5p axis plays a pivotal function on CRC progression.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Colorectal cancer (CRC); Metastasis; NORAD; Proliferation; miR-202-5p

Document Type: Research Article

Affiliations: 1: The First Department of General Surgery, Linyi Central Hospital, Linyi, Shandong Province, P.R. China 2: The First Department of Endocrinology, Linyi Central Hospital, Linyi, Shandong Province, P.R. China

Publication date: October 17, 2018

This article was made available online on February 22, 2018 as a Fast Track article with title: "LncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p".

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more